Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

Review

(5433) Total Article Views

Authors: Paula Rackoff

Published Date May 2009 Volume 2009:4 Pages 207 - 213

DOI: http://dx.doi.org/10.2147/CIA.S4080

Paula Rackoff

Division of Rheumatology, Beth Israel Medical Center, New York, NY, USA

Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.

Keywords: osteoporosis, fracture

Readers of this article also read: